The role of the ATM/Chk/P53 pathway in mediating DNA damage in hand-foot syndrome induced by PLD

Toxicology Letters

Volumn 265, Issue , 2017, Pages 131-139

  Yang, Jie ^a   Qiao, Long ^a   Zeng, Zhen ^a   Wang, Junnai ^a   Zhu, Tao ^a   Wei, Juncheng ^a   Wu, Mingfu ^a   Ye, Shuangmei ^a   Huang, Xiaoyuan ^a   Ma, Ding ^a   Liu, Ronghua ^a   Gao, Qinglei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; HaCaT cell; Pegylated liposomal doxorubicin (PLD); Zebrafish

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA; DOXORUBICIN; HISTONE H2AX; PROTEIN P53; ANTINEOPLASTIC ANTIBIOTIC; CELL CYCLE PROTEIN; MACROGOL DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE RESPONSE; DRUG MEGADOSE; EMBRYO; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HAND FOOT SYNDROME; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LOW DRUG DOSE; MALE; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN PIGMENTATION; ZEBRA FISH; ANALOGS AND DERIVATIVES; ANIMAL; CELL CYCLE; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HAND-FOOT SYNDROME; HUMAN; METABOLISM; NONMAMMALIAN EMBRYO; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE; CELL SURVIVAL; DNA DAMAGE; DOXORUBICIN; EMBRYO, NONMAMMALIAN; HAND-FOOT SYNDROME; HUMANS; KERATINOCYTES; POLYETHYLENE GLYCOLS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; ZEBRAFISH;

EID: 84999861950     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2016.11.024     Document Type: Article

References (30)

1. Al-Batran, S.E., Bischoff, J., von Minckwitz, G., Atmaca, A., Kleeberg, U., Meuthen, I., Morack, G., Lerbs, W., Hecker, D., Sehouli, J., Knuth, A., Jager, E., The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br. J. Cancer 94 (2006), 1615–1620.
2. Bartal, A., Mátrai, Z., Szûcs, A., Liszkay, G., Main treatment and preventive measures for hand-foot syndrome a dermatologic side effect of cancer therapy. Magy. Onkol. 55 (2011), 91–98.
3. Chen, Y.H., Lee, Y.T., Wen, C.C., Chen, Y.C., Chen, Y.J., Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish. Onco Targets Ther. 7 (2014), 1169–1175.
4. Del Bino, S., Bernerd, F., Variations in skin colour and the biological consequences of ultraviolet radiation exposure. Br. J. Dermatol. 169 (2013), 33–40.
5. El-Rayes, B.F., Ibrahim, D., Shields, A.F., LoRusso, P.M., Zalupski, M.M., Philip, P.A., Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. Invest. New Drugs 23 (2005), 57–62.
6. Gogolin, S., Ehemann, V., Becker, G., Brueckner, L.M., Dreidax, D., Bannert, S., Nolte, I., Savelyeva, L., Bell, E., Westermann, F., CDK4 inhibition restores G (1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle 12 (2013), 1091–1104.
7. Hauser, J.E., Kadekaro, A.L., Kavanagh, R.J., Wakamatsu, K., Terzieva, S., Schwemberger, S., Babcock, G., Rao, M.B., Ito, S., Abdel-Malek, Z.A., Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigm. Cell Res. 19 (2006), 303–314.
8. Köpper, F., Bierwirth, C., Schön, M., Kunze, M., Elvers, I., Kranz, D., Saini, P., Menon, M.B., Walter, D., Sørensen, C.S., Gaestel, M., Helleday, T., Schön, M.P., Dobbelstein, M., Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. PNAS 110 (2013), 16856–16861.
9. Kim, J.H., Chae, M., Kim, W.K., Kim, Y.J., Kang, H.S., Kim, H.S., Yoon, S., Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br. J. Pharmacol. 162 (2011), 773–784.
10. Kuo, L.J., Yang, L.X., Gamma-H2AX—a novel biomarker for DNA double-strand breaks. In Vivo 22 (2008), 305–309.
11. Lawrie, T.A., Bryant, A., Cameron, A., Gray, E., Morrison, J., Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst. Rev., 9, 2013, CD006910.
12. Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., Scambia, G., Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Ann. Oncol. 18 (2007), 1159–1164.
13. Maejima, Y., Adachi, S., Ito, H., Hirao, K., Isobe, M., Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 7 (2008), 125–136.
14. Mangana, J., Zipser, M.C., Conrad, C., Oberholzer, P.A., Cozzio, A., Knuth, A., French, L.E., Dummer, R., Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. Eur. J. Dermatol. 18 (2008), 566–570.
15. Marina, N.M., Cochrane, D., Harney, E., Zomorodi, K., Blaney, S., Winick, N., Bernstein, M., Link, M.P., Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin. Cancer Res. 8 (2002), 413–418.
16. Markman, M., Kennedy, A., Webster, K., Peterson, G., Kulp, B., Belinson, J., Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 78 (2000), 369–372.
17. Massey, A.J., Stokes, S., Browne, H., Foloppe, N., Fiumana, A., Scrace, S., Fallowfield, M., Bedford, S., Webb, P., Baker, L., Christie, M., Drysdale, M.J., Wood, M., Identification of novel in vivo active Chk1 inhibitors utilizing structure guided drug design. Oncotarget 6 (2015), 35797–35812.
18. Mohammad, N., Singh, S.V., Malvi, P., Chaube, B., Athavale, D., Vanuopadath, M., Nair, S.S., Nair, B., Bhat, M.K., Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: involvement of p53 and Fas receptor ligand complex. Sci. Rep., 7, 2015, 11853.
19. O'Brien, M.E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., Orlandi, F., Mellars, L., Alland, L., Tendler, C., CAELYX Breast Cancer Study Group, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15 (2004), 440–449.
20. Piegari, E., De Angelis, A., Cappetta, D., Russo, R., Esposito, G., Costantino, S., Graiani, G., Frati, C., Prezioso, L., Berrino, L., Urbanek, K., Quaini, F., Rossi, F., Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Res. Cardiol., 108, 2013, 334.
21. Rifkin, R.M., Gregory, S.A., Mohrbacher, A., Hussein, M.A., Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 106 (2006), 848–858.
22. Rose, P.G., Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 10 (2005), 205–214.
23. Sabuncuoglu, S., Antiapoptotic effect of aminoguanidine on doxorubicin-induced apoptosis. Mol. Cell. Biochem. 394 (2014), 129–135.
24. Smits, V.A., Gillespie, D.A., DNA damage control: regulation and functions of checkpoint kinase 1. FEBS J. 282 (2015), 3681–3692.
25. Spallarossa, P., Altieri, P., Aloi, C., Garibaldi, S., Barisione, C., Ghigliotti, G., Fugazza, G., Barsotti, A., Brunelli, C., Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am. J. Physiol. Heart Circ. Physiol. 297 (2009), H2169–H2181.
26. Spallarossa, P., Altieri, P., Barisione, C., Passalacqua, M., Aloi, C., Fugazza, G., Frassoni, F., Podestà, M., Canepa, M., Ghigliotti, G., Brunelli, C., p38 MAPK and JNK antagonistically control senescence and cytoplasmic p16INK4A expression in doxorubicin-treated endothelial progenitor cells. PLoS One, 5, 2010, e15583.
27. Taylor, W.R., Stark, G.R., Regulation of the G2/M transition by p53. Oncogene 20 (2001), 1803–1815.
28. von Gruenigen, V., Frasure, H., Fusco, N., DeBernardo, R., Eldermire, E., Eaton, S., Waggoner, S., A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 116 (2010), 4735–4743.
29. Wang, J., Ma, L., Tang, X., Zhang, X., Qiao, Y., Shi, Y., Xu, Y., Wang, Z., Yu, Y., Sun, F., Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells. Oncotarget 6 (2015), 24075–24091.
30. Yokomichi, N., Nagasawa, T., Coler-Reilly, A., Suzuki, H., Kubota, Y., Yoshioka, R., Tozawa, A., Suzuki, N., Yamaguchi, Y., Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum. Cell 26 (2013), 8–18.